Bristol-Myers Squibb Announces Charitable Donation of $6.9 Million to Support Cancer Patients

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) today announced a donation of $6.9 million in 2011 to support the HealthWell Foundation, an independent non-profit organization that provides financial assistance to eligible individuals to cover coinsurance, copayments, healthcare premiums and deductibles for certain treatments. The donation was made to HealthWell’s co-pay assistance funds to help underinsured cancer patients with their out-of-pocket disease related expenses that are not covered by their insurance plans, regardless of treatment selected.

“Bristol-Myers Squibb has robust patient assistance programs for cancer patients and this contribution reinforces our commitment to helping patients gain access to the medicines they need,” said John Tsai, vice president, U.S. Medical, Bristol-Myers Squibb. “We are proud to support the HealthWell Foundation in its mission to reduce barriers to care for underinsured patients.”

To learn more about HealthWell Foundation and to request assistance, patients and physicians should visit http://healthwellfoundation.org/ or call 800-675-8416.

In addition to its support of cancer patients, Bristol-Myers Squibb has a number of patient assistance programs in place in other disease areas for eligible patients. In 2011, the company helped more than 200,000 patients with free Bristol-Myers Squibb prescription medications estimated at more than $400 million through donations to the Bristol-Myers Squibb Patient Assistance Foundation as well as other programs. For more information on these programs, visit http://www.bms.com/products/Pages/programs.aspx.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com, or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb
Media: Amy Merves, 609-252-6934
[email protected]
or
Investors: John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Professional Services  Insurance  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.